PlainRecalls
FDA Drug Moderate Class II Terminated

Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets 10 mg/10 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 007045 USA, NDC 0591-2132-01

Reported: February 9, 2022 Initiated: January 18, 2022 #D-0461-2022

Product Description

Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets 10 mg/10 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 007045 USA, NDC 0591-2132-01

Reason for Recall

Failed Dissolution Specification: Dissolution results are below specification limits for the active ingredient

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
6205 100-count bottles
Distribution
Nationwide in the USA
Location
Parsippany, NJ

Frequently Asked Questions

What product was recalled?
Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets 10 mg/10 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 007045 USA, NDC 0591-2132-01. Recalled by Teva Pharmaceuticals USA. Units affected: 6205 100-count bottles.
Why was this product recalled?
Failed Dissolution Specification: Dissolution results are below specification limits for the active ingredient
Which agency issued this recall?
This recall was issued by the FDA Drug on February 9, 2022. Severity: Moderate. Recall number: D-0461-2022.